首页 | 本学科首页   官方微博 | 高级检索  
     

基于生物信息学分析ASPH在预测肺腺癌预后中的价值及机制研究
引用本文:怀琪琳1,' target='_blank'>2,韩连奎2,周军正1,' target='_blank'>2,舒 涵1,' target='_blank'>2,梅 宏1,' target='_blank'>2. 基于生物信息学分析ASPH在预测肺腺癌预后中的价值及机制研究[J]. 现代肿瘤医学, 2021, 0(18): 3216-3224. DOI: 10.3969/j.issn.1672-4992.2021.18.017
作者姓名:怀琪琳1  ' target='_blank'>2  韩连奎2  周军正1  ' target='_blank'>2  舒 涵1  ' target='_blank'>2  梅 宏1  ' target='_blank'>2
作者单位:1.遵义医科大学研究生院,贵州 遵义 563000;2.贵州省人民医院胸外科,贵州 贵阳 550000
基金项目:贵州省科技攻关项目(编号:黔科合SY字[2012]3101号)
摘    要:目的:探讨天冬氨酸β-羟化酶(ASPH)在肺腺癌中的表达情况、预后价值和在癌症中的作用机制。方法:使用Oncomine、GEPIA和TIMER数据库分析ASPH在肿瘤组织和正常组织中的表达差异,并用HPA数据库在蛋白水平验证,推测其临床意义。应用Kaplan-Meier plotter及GEPIA探讨ASPH表达水平与肺腺癌患者总生存时间的关系,提取Oncomine数据库中患者的生存信息加以整理分析,绘制生存曲线,研究ASPH表达水平与预后的关系。绘制ASPH蛋白互作网络,并进行功能富集分析,研究其作用机制。结果:来自Oncomine、GEPIA和TIMER数据库的数据均表示ASPH在肺腺癌组织中显著高表达(P<0.05),GEPIA数据库还证明了ASPH与肺腺癌患者病理分期显著相关。分析Oncomine数据表明,ASPH表达升高肺腺癌患者的生存时间更短(HR=0.39,95%CI:0.17~0.88,P=0.024 0),GEPIA及Kaplan-Meier plotter分析结果均支持ASPH高表达预示着肺腺癌患者预后更差(P=2.4E-08)。ASPH及相关基因功能涉及钙离子调控及缺氧反应,并参与Notch、mTOR信号通路,影响肿瘤的发生与发展。ASPH还与免疫细胞浸润及相关标志物呈现弱相关性。结论:ASPH在肺腺癌组织中表达明显升高,预示着患者预后不良,且参与多条与癌症相关的信号通路,与免疫细胞浸润呈现弱相关性,ASPH可能是肺腺癌新的预后和潜在治疗标志物。

关 键 词:ASPH  肺腺癌  预后  免疫细胞  生物信息学

The value and mechanism of ASPH in predicting the prognosis of lung adenocarcinoma based on bioinformatics
HUAI Qilin1,' target='_blank'>2,HAN Liankui2,ZHOU Junzheng1,' target='_blank'>2,SHU Han1,' target='_blank'>2,MEI Hong1,' target='_blank'>2. The value and mechanism of ASPH in predicting the prognosis of lung adenocarcinoma based on bioinformatics[J]. Journal of Modern Oncology, 2021, 0(18): 3216-3224. DOI: 10.3969/j.issn.1672-4992.2021.18.017
Authors:HUAI Qilin1  ' target='_blank'>2  HAN Liankui2  ZHOU Junzheng1  ' target='_blank'>2  SHU Han1  ' target='_blank'>2  MEI Hong1  ' target='_blank'>2
Affiliation:1.Department of Graduate School,Zunyi Medical University,Guizhou Zunyi 563000,China;2.Department of Thoracic Surgery,Guizhou Provincial People's Hospital,Guizhou Guiyang 550000,China.
Abstract:Objective:To investigate the expression,prognostic value and mechanism of Aspartyl/Asparaginyl beta-hydroxylase (ASPH) in lung adenocarcinoma (LUAD).Methods:Oncomine,GEPIA and TIMER database were used to analyze the difference of ASPH expression in tumor tissues and normal tissues,and the HPA database was used to verify the protein level to speculate its clinical significance.Kaplan-Meier plotter and GEPIA were used to explore the relationship between ASPH expression level and the overall survival time of LUAD patients.The survival information of patients in Oncomine database was extracted and analyzed,and survival curves were drawn to study the relationship between ASPH expression level and prognosis.The ASPH protein-protein interaction network was drawn,and functional enrichment analysis was performed to study its mechanism of action.Results:The data from Oncomine,GEPIA and TIMER database showed that ASPH was highly expressed in LUAD tissues (P<0.05).The GEPIA database also proved that ASPH was significantly related to the pathological stage of patients with LUAD.The analysis of Oncomine data showed that the survival time of LUAD patients with increased ASPH expression was shorter (HR=0.39,95%CI:0.17~0.88,P=0.024 0),and the results of GEPIA and Kaplan-Meier plotter all supported that the high expression of ASPH predicted poor prognosis of LUAD patients (P=2.4E-08).The functions of ASPH and related genes involved calcium ion regulation and hypoxic response,and participated in Notch and mTOR signaling pathways,affecting occurrence and development of tumors.There was also a weak correlation between ASPH and immune infiltrating cells and related markers.Conclusion:The expression of ASPH in LUAD tissues is significantly increased,and it indicates the poor prognosis and participates in multiple cancer-related signaling pathways.ASPH may be a new prognosis and potential therapeutic target for LUAD.
Keywords:ASPH   lung adenocarcinoma   prognosis   immune cell   bioinformatics
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号